Protein family review

The reticulons: a family of proteins with diverse functions
Yvonne S Yang and Stephen M Strittmatter

Address: Program in Cellular Neuroscience, Neurodegeneration and Repair, Department of Neurology, Yale University School of Medicine, New Haven, CT 06536, USA.

Correspondence: Stephen M Strittmatter. Email: stephen.strittmatter@yale.edu

Published: 28 December 2007

Summary

The reticulon family is a large and diverse group of membrane-associated proteins found throughout the eukaryotic kingdom. All of its members contain a carboxy-terminal reticulon homology domain that consists of two hydrophobic regions flanking a hydrophilic loop of 60-70 amino acids, but reticulon amino-terminal domains display little or no similarity to each other. Reticulons principally localize to the endoplasmic reticulum, and there is evidence that they influence endoplasmic reticulum-Golgi trafficking, vesicle formation and membrane morphogenesis. However, mammalian reticulons have also been found on the cell surface and mammalian reticulin 4 expressed on the surface of oligodendrocytes is an inhibitor of axon growth both in culture and in vivo. There is also growing evidence that reticulons may be important in neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis. The diversity of structure, topology, localization and expression patterns of reticulons is reflected in their multiple, diverse functions in the cell.

Gene organization and evolutionary history

Proteins of the reticulon family are present in all eukaryotic organisms examined and range in size from 200 to 1,200 amino acids. The vertebrate proteins of this family are called reticulons (RTNs) and those found in other eukaryotes are called reticulon-like proteins (RTNLs). All family members contain the reticulon homology domain (RHD), a conserved region at the carboxy-terminal end of the molecule consisting of two hydrophobic regions flanking a hydrophilic loop. Reticulons have been identified in the genomes of Homo sapiens, Mus musculus, Danio rerio, Xenopus laevis, Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana, Saccharomyces cerevisiae and many other eukaryotes, but not in archaea or bacteria [1-6]. The ubiquity of reticulons in the eukaryotic kingdom is consistent with a highly conserved function and/or a diversity of functions.

Nearly all reticulon genes contain multiple introns and exons, and most are alternatively spliced into multiple isoforms [1]. Intron losses and gains over the course of evolution have given rise to the large, diverse reticulon family. The presence of reticulons in eukaryotic but not prokaryotic organisms and their close association with the endoplasmic reticulum (ER) suggest that reticulons evolved along with the eukaryotic endomembrane system.

Across phyla, the second hydrophobic region of the RHD is the most highly conserved, followed by the first hydrophobic region, with the carboxyl terminus the least conserved [7]. In mammals, there are four reticulon genes encoding reticulon proteins RTN1-4. The RHDs of RTN1, 3 and 4 share the highest sequence identity at the amino-acid level (average 73%), whereas RTN2 has only 52% identity with human RTN4 (Figure 1). The amino-acid sequence identity between RHDs of C. elegans and S. cerevisiae drops to 15-50%.

In contrast to the highly conserved carboxy-terminal RHD, the amino-terminal regions of reticulons display no sequence similarity at all, even among paralogs within the same species [8]. Furthermore, the expression patterns of different
reticulons and their splice isoforms can be variable, even within the same organism [9-11]. This divergence in sequence and expression is consistent with evolution of species- and cell-type-specific roles for reticulons [12]. This is particularly clear in the mammalian RTN family, in which the longest isoform of RTN4, RTN4A, also known as Nogo-A, has been shown to inhibit neurite outgrowth and axon regeneration in models of injury [8,13-18]. Interestingly, RTN4A was found to be absent in fishes, organisms in which there is extensive regeneration of the CNS after injury [4]. Divergent results for genetic knockouts of different regions and isoforms of RTN4 suggest that the amino-terminal domain might contribute to the inhibition of nerve regeneration after injury [12]. Thus, the divergent reticulon amino-terminal domains appear to carry out species- and cell-specific roles, whereas the RHD may carry out more basic cellular functions.

**Characteristic structural features**

The RHD consists of two hydrophobic regions, each 28-36 amino acids long, which are thought to be membrane-embedded regions, separated by a hydrophilic loop of 60-70 amino acids, and followed by a carboxy-terminal tail about 50 amino acids long (Figure 2a). Although much amino-acid identity has been lost over the course of evolution, the overall structure of the RHD has been preserved from plants to yeasts to humans. This suggests that three-dimensional protein structure is of greater importance than individual residues for RHD function. The RHD hydrophobic regions are unusually long for transmembrane domains: each spans approximately 30-35 amino acids, whereas most transmembrane domains are about 20 amino acids in length. This raises the interesting question of whether this longer length has significance for reticulon function. The topology of these hydrophobic regions within membranes is so far only partially defined.

**Reticulon topology**

The RHD loop region has been detected both on the surface of cells and intracellularly, and it has been suggested that the RHD hydrophobic domains might either span the ER membrane or plasma membrane completely or might double back on themselves to form a hairpin (Figure 2b). Antibodies against the amino-terminal domain of RTN4
bind to the surface of chick oligodendrocytes in live spinal cord explants [8] and cultured oligodendrocytes interact specifically with both amino-terminal domain-specific antibodies and antibodies directed against the RTN4 66-amino-acid loop (66-loop) [16]. These findings suggest that the amino terminus and the 66-loop project into extracellular space, and therefore that the first RHD hydrophobic region must double back on itself in the membrane. However, other data suggest that the amino-terminal domain is intracellular. Antibodies against the 66-loop region of RTN4 detect small amounts of this epitope on the surface of live COS-7 cells, but antibodies against c-Myc tags fused to either the amino or the carboxy terminus do not bind to live cells [8].

More recent data from non-neuronal cells in which RTN4 is overexpressed strongly support a third model, in which most of both the amino-terminal domain and the 66-loop are cytoplasmic. In COS cells treated with maleimide polyethylene glycol, cysteines in the amino-terminal domain and the loop regions of ER-associated RTN4 were found to be modified by the reagent after detergent disruption of the plasma membrane but not the ER membrane [6]. Cysteines in the carboxy-terminal region were only partially modified. All these results suggest that mammalian reticulons might have different topologies in the ER and plasma membranes; such multiple conformations may enable them to carry out multiple roles in the cell. Another protein with multiple membrane topologies is the mammalian prion protein (PrP);

Figure 2
The structure and membrane topology of reticulons. (a) Structure of reticulon proteins. Numbers refer to the exons that encode the protein regions. Black ovals represent hydrophobic regions. GenBank accession numbers are as in Figure 1. (b) Possible topologies of reticulon proteins in membranes. Although eight or more conformations are possible, only those for which evidence exists are depicted. Different topologies in different cell types and different membranes may enable reticulons to carry out diverse roles in the cell.
overexpression of a certain transmembrane form of the prion protein, \(^{13}PrP\), causes neurodegenerative disease distinct from that caused by the natural pathogenic prion form \(PrP^{SC}\) [19,20]. Another possibility is that reticulons assume different topologies in different cell types: the reticulon amino-terminal region has been detected only in the cytoplasm in COS-7 cells, but has been found on both the surface and in the cytoplasm of oligodendrocytes. Again, this may reflect the diverse roles of reticulin proteins in different cell types.

**Reticulon tertiary structure**

The solution structure of the RHD loop of RTN4, known as Nogo66, has recently been probed by circular dichroism (CD) and nuclear magnetic resonance (NMR). Nogo66 is soluble in pure water and consists of three alpha helices, two short flanking one long, spanning residues 6-15, 21-40 and 45-53, followed by the unstructured residues 55-60 [21,22]. The Nogo66 loop is involved in several RTN4-specific signaling cascades, including interaction with the Nogo receptor (NogoR) to inhibit neurite outgrowth [23], and with the cell adhesion molecule contactin-associated protein (Caspr) [24] to mediate the localization of potassium channels at axonal paranodes. The human RTN1 and RTN3 66-loops share 71% and 63% identity with the RTN4 loop; mouse RTN1 and RTN3 identity with human RTN4 is 67% and 59%. Despite this high degree of identity, the RTN1 66-loop does not bind to NogoR, and the function of the 66-loops in RTN1 and RTN3 is unknown in both mammals and lower organisms.

As mentioned above, the amino-terminal regions of different reticulons are highly divergent in sequence. The amino-terminal domains of the human RTN4 isoforms appear to be highly unstructured, even under physiological conditions. *In silico* analysis and measurements by CD and NMR of the human isoforms RTN4A and RTN4B reveal a high degree of disorganization, with only short alpha helices and beta sheets that exist transiently [25]. Recent studies have shown that intrinsically unstructured proteins (IUPs) are more likely to form multiprotein complexes than are proteins with stable tertiary structure [26], are better able to ‘moonlight’ - carry out alternative functions [25] - and may fold upon binding to their partners [27]. It has been shown that up to 33% of eukaryotic proteins contain long disordered regions, compared with 2% of archael proteins [25]. The characterization of RTN4 as an intrinsically unstructured/disordered protein may explain its involvement in many physiological processes, as explained below.

**Localization and function**

The first known reticulin protein, RTN1, was identified from a cDNA in neural tissue [28] and subsequently characterized as an antigen specific to neuroendocrine cells [29]. This so-called neuroendocrine-specific protein (NSP) was later renamed reticulin when it was discovered by both immuno-

histochemical and biochemical methods to be associated with the ER in COS-1 cells [30]. Reticulons do not contain an ER localization sequence per se, but a single RHD hydrophobic region is sufficient to target an enhanced green fluorescent protein-RTN fusion protein to the ER, whereas deletion of the RHD abolishes association with the ER [13,31]. Reticulons have been shown to localize to the ER in yeast, *Arabidopsis*, *C. elegans*, *Xenopus*, *Drosophila* and mammals [2,3,5,6,32-34]. Most reticulin research has focused on RTN4 in the CNS and its effects on neurite outgrowth and axonal regeneration after spinal cord injury. However, the presence of reticulons in all eukaryotic organisms and their ubiquitous ER-associated expression indicate a more general role. We shall focus on three areas of reticulin localization and function: ER-associated roles, oligodendrocyte-associated roles in inhibition of neurite outgrowth, and the role of reticulons in neurodegenerative diseases.

**ER-associated reticulons and their function**

There is growing evidence that reticulons are involved in bending and shaping the ER membrane, in trafficking of material from the ER to the Golgi apparatus, and in apoptosis (Figure 3). Antibody-mediated inhibition of RTN4A in mammalian cells prevents GTP-induced formation of elongated membrane tubules *in vitro* [6], and knocking out both the *C. elegans* RTNL RET-1 and its associated protein YOP-1 interferes with ER formation during mitosis in the worm [33]. RTN4A also localizes to subdomains of the *Xenopus* nuclear envelope, and its inhibition by anti-RTN4A antibodies limits nuclear envelope assembly [35]. *C. elegans* RET-1 also interacts with the protein RME-1, a regulator of endocytic recycling [36-38]. In a yeast two-hybrid screen, the mammalian RTN1 isoforms RTN1A and RTN1B were found to interact with a component of the mammalian endocytosis adaptor complex AP-2. RTN1C, in contrast, may be involved in exocytosis. It associates with calreticulin-negative regions of the ER and co-immunoprecipitates with the SNARE proteins syntaxin 1, syntaxin 7, syntaxin 13 and VAMP2 [39]. Overexpression of a fragment of RTN1C increases the rate of exocytosis in PC12 cells. RTN1, RTN2, and RTN4 were all identified in a yeast two-hybrid screen using the vesicle fusion protein chaperone β-SNAP as bait, although these results were not confirmed by co-immunoprecipitation [40]. In summary, reticulons interact with proteins involved in vesicular formation and fusion such as SNAREs and SNAPs. Reticulons also appear to play a role in ER morphogenesis; nevertheless, cells lacking reticulin expression do not have major defects in ER, endosomal or microsomal structure.

Reticulons are also involved in intracellular trafficking - a close cousin of vesicle formation and recycling. Over-expression of RTN3 in HeLa cells prevents retrograde transport of proteins from the Golgi complex to the ER [41]. In yeast, RTNL1B forms complexes with Yip3p, the yeast ortholog of the mammalian Rab-GDI displacement protein-RTN fusion protein to the ER, whereas deletion of the RHD abolishes association with the ER [13,31].
factor (GDF). Small GTPases of the Rab family facilitate vesicle trafficking between organelles, and are regulated by GDFs [42]. In C. elegans, inhibition of RET-1 and YOP-1 disrupted nuclear envelope assembly, and of 29 Rabs screened, depletion of Rab5 mimicked this phenotype closely [33]. In a screen in human cells for GTPase-activating proteins (GAPs), which inhibit Rab function, the protein TBC1D20 was found to be a GAP for Rab1 and Rab2, and in the same study, interaction between RTN1C and TBC1D20 was identified in a yeast two-hybrid screen, a further argument for a role for reticulons as regulators of Rab-regulated intracellular trafficking [43].

In mammalian cells, reticulons may also play a role in apoptosis. Both RTN1C and what is now known to be RTN4A were identified in a screen for interactors with Bel-XL, a powerful inhibitor of apoptosis [44]. RTN1C was found to inhibit Bel-XL, and RTN4A was found to inhibit both Bel-XL and another apoptosis inhibitor, Bcl-2, demonstrating a pro-apoptotic role for reticulons. More recently, RTN1C was shown to modulate apoptosis by upregulating the sensitivity of the ER to stressors in neuroblastoma cells [45]. Several labs have shown that RTN3 also enhances apoptosis via interaction with Bcl-2 [46-48]. Although these and other data indicate that reticulons may have a role in tumor suppression via upregulation of apoptosis, this topic is not without controversy [49].

**Oligodendrocyte reticulon and its role in neurite outgrowth inhibition**

The longest isoform of RTN4, RTN4A, has been extensively characterized in the mammalian CNS (recently reviewed by...

---

**Figure 3**

The expression and function of reticulons. (a) Myc-tagged reticulon constructs transfected into COS-7 cells show a reticular expression pattern. Scale bar, 70 µm. (b) Proteins known to interact with ER-associated and intracellular reticulons and their possible intracellular roles. Some classes of proteins may overlap in their cellular functions.
Liu et al. [50]. It had long been known that in contrast to the myelin of the peripheral nervous system, myelin from the CNS appeared to prevent neuronal regeneration after injury [51]. In 1988, by size fractionation of rat CNS myelin, Caroni and Schwab discovered a 250 kDa inhibitor of neurite outgrowth [52]. This protein was later identified as a novel reticulon (RTN4A) and also named Nogo-A after its inhibitory effect on neuronal regeneration [8,13,14]. As the protein is generally called by this name in neuronal regeneration studies, we shall use that name in the following discussion.

GrandPré et al. [8] showed that the extra-cellular/ER luminal portion of Nogo-A, the 66-loop termed Nogo66, is a potent inhibitor of neurite outgrowth. The receptor for Nogo66 was subsequently identified and termed NogoR [23]. Inhibition of NogoR using the antagonist peptide NEP1-40 releases myelin-mediated inhibition of neurite outgrowth in culture, and both the acute intrathecal delivery and delayed systemic delivery of NEP1-40 promotes axonal regeneration of corticospinal tract fibers after dorsal hemisection in rats [18,53-55]. Work on the amino-terminal domain of Nogo-A demonstrated its capacity to induce growth-cone collapse independent of NogoR via a region now called Δ20 [16,23], whereas another amino-terminal region, termed Nogo-A-24, is known to enhance the binding affinity of Nogo66 for NogoR when fused to Nogo66 [15]. Interestingly, the RHD region common to all isoforms of Nogo (RTN4) is alone sufficient to delay nerve regeneration after sciatic nerve crush [56].

Numerous in vivo studies in animals have found that either genetic ablation or pharmacological inhibition of the Nogo-A-NogoR interaction promotes axon growth and behavioral recovery after spinal cord injury [17,18,53,54,57-62], and significant improvement of recovery after similar prevention of Nogo-A action is also seen after stroke injury [63-65]. The field is not free from controversy, however [66,67]. The genetic background can alter the effects of Nogo inhibition [68], and studies of spinal cord injury in Nogo-knockout animals generated in different laboratories have yielded variable results [69-71]. The weight of evidence for a role for Nogo-A as an inhibitor of neurite outgrowth and a limitor of axon growth in spinal cord injury, however, make it a prime target for therapeutic intervention. Indeed, clinical trials of anti-Nogo antibodies are already under way.

Although the mechanism of action of reticulon in the ER remains to be elucidated, the mechanism by which Nogo-A inhibits neurite outgrowth and axon regeneration in the CNS is well characterized (Figure 4, Table 1). The receptor - NogoR - for the Nogo66 region was identified in 2001 [21], but this receptor lacks a transmembrane and signaling domain and so must interact with a co-receptor or other signal transducer. Several candidates for this role have been discovered: the neurotrophin receptor p75, the transmembrane protein LINGO-1 and the orphan tumor necrosis factor family member TAJ/TROY have all been shown to bind NogoR and participate in the inhibition of neurite outgrowth in vitro [72-78] (see Figure 4, Table 1). The epidermal growth factor receptor (EGFR) may indirectly be a signal transducer for NogoR - the kinase activity of EGFR has been shown to be required for the inhibitory action of Nogo66 in culture - but EGFR does not directly bind NogoR [78]. A crystal structure of the ligand-binding domain of the NogoR receptor has been determined [79,80]. NogoR and all its putative co-receptors rely on the small GTPase RhoA for their downstream effects. Upon RhoA activation as a result of NogoR signaling, Rho-activated kinase (ROCK) stimulates actinomyosin activity, causing growth-cone collapse [50,81]. Blocking Rho activity either pharmacologically or with dominant-negative RhoA releases Nogo66-mediated neurite outgrowth inhibition in vitro [82-85].

Frontiers

Many aspects of our knowledge of the reticulon protein family remain incomplete. There is no consensus on the mechanism(s) underlying the ER-associated function of reticulons, and debate continues over the role of mammalian Nogo-A in the inhibition of neurite outgrowth. The most exciting frontier of reticulon research, however, is in the field of neurodegenerative disease. There is growing evidence that reticulons may have a role in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, multiple sclerosis and perhaps hereditary spastic paraplegia.

In 2004 it was found that all four human reticulon proteins interact with the enzyme that produces the pathologic agent in Alzheimer’s disease. He et al. [86] showed that BACE1, the β-secretase that cleaves amyloid precursor protein (APP) into β-amyloid peptide (Aβ), co-immunoprecipitates with RTN1, RTN2, RTN3 and RTN4 [86]. In vitro, over-expression of a single RTN reduced the levels of Aβ produced by HEK-293 cells expressing the Swedish mutant of APP, and conversely, knockdown of RTN3 by RNA interference increased Aβ levels [54]. More recently, Murayama and colleagues screened for proteins that interact with BACE1 and identified RTN3 and RTN4 [87]. These authors also demonstrated decreased Aβ production in cells expressing the Swedish mutant [87]. Notably, in a subtractive hybridization screen, Yokota and colleagues [88] found that human RTN3 was downregulated in the temporal lobes of Alzheimer's patients. Although these data are intriguing, the exact role of reticulons in Alzheimer's disease remains unknown, and further investigation is needed to confirm whether these proteins may be potential therapeutic targets in Alzheimer's disease.

Reticulons have also been found to be involved in ALS. In an ALS mouse model expressing human superoxide dismutase (SOD) containing a disease-causing dominant mutation, Dupuis et al. [89] found differential up- and
downregulation of RTN4A and RTN4C mRNA compared with wild-type mice. Jokic et al. [90] demonstrated that levels of RTN4 in muscle biopsies of ALS patients correlated with disease severity. Pradat et al. [91] found that expression of RTN4A in lower motor neuron syndromes was prognostic of ALS, but Wojcik and colleagues [92] have found recently that RTN4A expression is not unique to ALS. Genetic analysis of RTN4 in the SOD mouse model of ALS shows that it has a significant impact on survival [93]. Importantly, this effect on survival does not seem to be due to a direct effect on mutant SOD levels (YSY and SMS, unpublished data), and may instead be related to the roles of RTN4A in vesicle formation and trafficking. It is of note that RTN4A levels in muscle increase in surgically denervated wild-type mice [94], and as mentioned above, other groups have found that changes in RTN4A expression are not necessarily specific to ALS [92]. Considering the impact of RTN4 in the mouse model of ALS, however, this protein remains a possible candidate drug target for the disease.

Lastly, RTN4 may have a role in multiple sclerosis and hereditary spastic paraplegia. Autoantibodies against the isoform A-specific region of RTN4 have been found in serum and cerebrospinal fluid of patients with multiple sclerosis [95]. Interestingly, administration of exogenous anti-RTN4A antibodies protects against demyelination in the experimental autoimmune encephalitis mouse model of multiple sclerosis [96]. Spastin, the most commonly mutated protein in hereditary spastic paraplegia, was found to interact with RTN1 and RTN3 via yeast two-hybrid screening; the interaction between spastin and RTN1 was further confirmed by co-immunoprecipitation and co-localization of the two proteins in transfected HeLa cells [97,98].

Questions remain regarding all aspects of the reticulon family, from its most basic characteristics such as membrane topology to its partners in intracellular trafficking, to the downstream signaling molecules that effect the reticulons' influence on human disease. Despite the lack of consensus about the mechanism of action of reticulons in normal cellular function and in neurodegenerative disease, their involvement in several disease processes makes them important targets for therapeutic development.

Acknowledgements

This work was supported by an NIH Institutional Medical Scientist Training award to YSY and by grants to SMS from the NIH, the Wings for Life Foundation, the Falk Medical Research Trust and the Christopher Reeve Paralysis Foundation.

| Table 1 | Co-receptors and signal transducers in the Nogo-A-NogoR interaction |
|----------------|------------------------------------------------------------------|
| Molecular region/interactor | Function/interaction | Reference(s) |
| NogoA-24 | Increases binding affinity of Nogo-A to Nogo receptor (NogoR); binds NogoR directly | [15] |
| ∆20 | Mediates fibroblast and growth cone collapse independently of NogoR | [16] |
| p75NTR | Neurotrophin receptor; binds NogoR and mediates inhibition of neurite outgrowth via myelin-associated inhibitors | [72,73] |
| LINGO-I | Binds NogoR; activates Rho in complex with p75 and NogoR; mediates Nogo66-induced neurite outgrowth inhibition | [74,75] |
| TAJ/TROY | Binds NogoR, activates Rho in complex with LINGO-I and NogoR; absence attenuates myelin inhibition of neurite outgrowth | [76,77] |
| EGFR | Kinase activity required for neurite outgrowth but EGFR does not bind NogoR | [78] |

Figure 4

Interaction of Nogo-A with Nogo receptor. The interaction of Nogo-A (RTN4A) on oligodendrocytes and the Nogo receptor (NogoR) on neurons results in inhibition of axon regeneration after injury via Rho signaling [17,23,55,59,61-63,79]. The different regions of Nogo-A are colored as follows: red, 66-loop (Nogo66); green, Nogo-A-24; blue, ∆20. NogoR is in orange. The 66-loop interacts with NogoR to mediate growth-cone collapse and neurite outgrowth in vitro and to inhibit axon regeneration after injury [21,23,25,53,56,58,60,62]. The amino-terminal region Nogo-A-24 increases the binding affinity of Nogo-A to NogoR and also binds NogoR directly [15]. The amino-terminal region ∆20 can mediate fibroblast and growth-cone collapse independently of NogoR [16]. Some known co-receptors and signal transducers are listed beside the yellow symbol and are described in more detail in Table 1.
References

1. Oertle T, Klinger M, Stuermer CA, Schwab ME: A reticular rhy-  
   sodyme: phylogenetic evolution and nomenclature of the RTN/  
   Nogo gene family. FASEB J 2003, 17:1283-1297.

2. Nziengui H, Bouhidel K, Pillon D, Der C, Marty F, Schoefs B: Reticul-  
   ulon-like proteins in Arabidopsis thaliana: structural organiza-  
   tion and ER localization. FEMS Lett 2007, 581:3356-3362.

3. Wakefield S, Tear G: The Drosophila retilcon, Rtn-1, has mul-  
   tiple differentially expressed isoforms that are associated with a sub-  
   compartment of the endoplasmic reticulum. Cell  
   Mol Life Sci 2006, 63:2027-2038.

4. Diekmann H, Klinger M, Oertle T, Heinz D, Pogoda HM, Schwab ME,  
   Stuermer CA: Analysis of the retilcon gene family demonstra-  
   tes the absence of the neurite growth inhibitor Nogo-A in fish.  
   Mol Biol Evol 2005, 22:1635-1648.

5. Moreira EF, Jaworski CJ, Rodriguez IR: The N- and C-termi-  
   nus of the human Nogo molecules are intrinsically unstructured:  
   bioinformatics, CD, NMR characterization, and functional impli-  
   cations. Proteins 2007, 68:100-108.

6. Voeltz GK, Prinz WA, Shibata Y, Rau J: A class of  
   neurons projecting to the tubular endoplasmic reticulum.  
   Cell 2006, 124:573-586.

7. Yan R, Shi Q, Hu X, Zhou X: Reticulon proteins: emerging  
   players in neurodegenerative diseases. Cell Mol Life Sci 2006,  
   63:877-889.

8. Prinjha R, Moore SE, Vinson M, Blake S, Morrow R, Christie G,  
   Raul JS, Ludes B, Loeffler JP: Tissue specificity and reg-  
   ulation of the N-terminal diversity of retilcon 3. Biochem  
   J 2005, 385:439-444.

9. Huber AB, Weimann O, Brosamle C, Oertle T, Schwab ME: Pat-  
   terns of nogo mRNA and protein expression in the develop-  
   ing and adult rat and after CNS lesions. J Neurosci 2002, 22:  
   3553-3567.

10. Wang X, Chen SJ, Troalz H, Vantaran T, Greer CA, Sturtzman  
    S: Localization of Nogo-A and Nogo-66 receptor proteins  
    at sites of axon-myelin and synaptic contact. J Neurosci 2002,  
    22:5505-5515.

11. Hunt D, Coffey AS, Prinjha RK, Campbell G, Anderson PN: Nogo-A  
    expression in the intact and injured nervous system. Mol  
    Neurosci 2003, 24:1083-1102.

12. Di Scala F, Dupuis L, Gaidton C, De Tapia M, Jokic N, Gonzalez de  
    Aguilar JL, Raul JS, Ludes B, Loeffler JP: Analysis of the reticulon  
    gene family (RTN3): gene struc-  
    ture and chromosomal localization to 11q13. Genomics  
    1999, 58:73-81.

13. Nziengui H, Bouhidel K, Pillon D, Der C, Marty F, Schoefs B:  
    Cloning of a novel member of the retilcon gene family (RTN3): gene  
    structure and chromosomal localization to 11q13. Genomics  
    1999, 58:73-81.
protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 2000, 19:5736-5746.

45. Di Sano F, Fazi B, Tuft R, Gardacci R, Plascenzi M: Reticulon-1 acts as a molecular switch between endoplasmic reticulum stress and genotoxic cell death pathway in human neuroblastoma cells. J Neurochem 2007, 102:345-353.

46. Zhu L, Xiang R, Dong W, Liu Y, Qi Y: Anti-apoptotic activity of Bcl-2 is enhanced by its interaction with RTN3. J Cell Biol Int 2007, 31:825-830.

47. Wang Q, Kang E, Dong W, Zhou S, Xu H, Liu Q: ER Ca"2+ depletion triggers apoptosis signals for endoplasmic reticulum (ER) overload response induced by overflow expression of reticulon 3 (RTN3/ HAP). J Cell Physiol 2005, 204:549-559.

48. Oertle T, Merkler D, Schwab ME: Do cancer cells die because of Nogo-B? Oncogene 2003, 22:1390-1399.

49. Liu BP, Cafferty WB, Bident SO, Strittmatter SM: Extracellular reg u-lators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond 2006, 361:1593-1610.

50. David S, Aguayo AJ: Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. J Neurosci Res 2001, 64:293-313.

51. Caroni P, Schwab ME: Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibrilloblast spreading. J Cell Biol 1988, 106:1281-1288.

52. GrandPre T, Strittmatter SM: Nogo receptor antagonist peptide promotes axonal regeneration. Nature 2002, 417:547-551.

53. Li S, Liu BP, Bident SO, Li M, Li J, Wu M, Xin J, Rabacchi S, Choi E: Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 2004, 24:10511-10520.

54. Kim JE, Liu BP, Park JH, Strittmatter SM: Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 2004, 44:439-451.

55. Kim JE, Bonilla IE, Qiu D, Strittmatter SM: Nogo-C is sufficient to delay nerve regeneration. Mol Cell Neurosci 2003, 23:451-459.

56. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME: Recovery from spinal cord injury and treatment with the anti-Nogo-A antibody IN-1. Neuron 2007, 54:99-109.

57. Fournier AE, Takizawa BT, Strittmatter SM: Nogo receptor antagonist peptide limits functional recovery from spinal cord injury. Neuron 2003, 38:201-211.

58. Cafferty WB, Strittmatter SM: The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J Neurosci 2006, 26:12242-12250.

59. Li S, Strittmatter SM: Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 2003, 23:4219-4227.

60. Lee JK, Kim JE, Sivula M, Strittmatter SM: Nogo receptor antagonists promote stroke recovery by enhancing axonal plasticity. J Neurosci 2004, 24:6209-6217.

61. Papadopoulos CM, Tsai SY, Westwood JL, Bollnow MR, Kolb BE, Schwab ME, Karcie GL: Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-A neutralization. Cereb Cortex 2006, 16:529-536.

62. Papadopoulos CM, Tsai SY, Alsbiel T, O'Brien TE, Schwab ME, Karcie GL: Functional recovery and neuroanatomical plasticity following middle cerebral arterial occlusion and IN-1 antibody treatment in the adult rat. Ann Neurol 2002, 51:433-441.

63. Steward O, Zheng B, Baros K, Yee KM: Response to: Kim et al., "Axon regeneration in young adult mice lacking Nogo-A/B." Neuron 38, 187-199. Neuron 2007, 54:195-199.

64. Crusio W, Schnell L, Montani L, Duncan C, Simonen M, Schneider R, Liebscher T, Gullo M, Schwab ME: Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. J Neurosci 2006, 26:5591-5603.

65. Zheng B, Ho C, Li S, Keirstead H, Steward O, Tessier-Lavigne M: Lack of enhanced spinal regeneration in Nogo-deficient mice. Neuron 2003, 38:213-224.

66. Woolf CJ: No Nogo: now where to go? Neuron 2003, 38:153-156.

67. Zheng B, Atwal J, Ho C, Case L, He XL, Garcia KC, Steward O, Tessier-Lavigne M: Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci USA 2005, 102:205-210.

68. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z: PTX interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMO. Nature 2002, 420:74-77.

69. Domeniconi M, Zampieri N, Spencer T, Hilaire M, Mellado W, Chao MV, Filbin MT: MAG induces regulated intramembrane proteolysis of the p75 neurotrophin receptor to inhibit neurite outgrowth. Neuron 2003, 38:345-352.

70. Li S, Liu BP, Bident SO, Li M, Li J, Wu M, Xin J, Rabacchi S, Choi E: Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 2004, 24:10511-10520.

71. Wang S, Zhao B, Liu J, Lee X, Scott ML, Sluga-Morskaya S, Zang Y, Jaccoud D, Levesque M, Allaire N, Perrin S, Sands B, et al.: LINGO-1 is a component of the Nogo-66 receptor/toll signaling complex. Nat Biotechnol 2007, 25:453-359.

72. Koprivica V, Cho KS, Park JB, Yiu G, Atwal J, Ghe B, Kim JA, Lin E, Tessier-Lavigne M, Chen DF, et al.: EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 2005, 310:106-110.

73. Barton WA, Liu BP, Tsvetkova D, Jeffrey PD, Fournier AE, Sah D, Case K, Strittmatter SM, Nikolov DB: Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J 2003, 22:3329-3330.

74. Xu XL, Bazan FG, G M, Park JB, Wang K, Tessier-Lavigne M, Ho Z, Garcia KC: Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron 2003, 38:177-185.

75. Fournier AE, Kalb RG, Strittmatter SM: Rho GTPases and axonal outgrowth cone collapse. Methods Enzymol 2000, 325:473-482.

76. Fournier AE, Tsakiriotis BW, Strittmatter SM: Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003, 23:1416-1423.

77. Elzebaz B, Dubreuil C, Winton M, Loy L, Dergham P, Selles-Navarro I, McKerracher L: Inactivation of intracellular Rho to stimulate axon growth and regeneration. Prog Brain Res 2002, 137:371-380.

78. Dergham P, Elzebaz B, Essagian C, Avendissian H, Lubell WD, McKerracher L: Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002, 22:6570-6577.

79. Lehmann M, Fournier A, Selles-Navarro I, Dergham P, Sebok A, Leclerc N, Tigyi G, McKerracher L: Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999, 19:7537-7547.

80. He W, Lu Y, Qaiwash I, Hu XY, Chang A, Yan R: Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 2004, 10:599-605.

81. Murayama KS, Kametani F, Saito S, Kume H, Akiyama H, Arai W: Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta protein. Eur J Neurosci 2006, 24:1237-1244.
88. Yokota T, Mishra M, Akatsu H, Tani Y, Miyachi T, Yamamoto T, Kosaka K, Nagai Y, Sawada T, Heese K: Brain site-specific gene expression analysis in Alzheimer's disease patients. Eur J Clin Invest 2006, 36:820-830.

89. Dupuis L, Gonzalez de Aguilar JL, di Scala F, Rene F, de Tapia M, Pradat PF, Lacomblez L, Seilhan D, Prinjha R, Walsh FS, et al.: Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002, 10:358-365.

90. Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna A, Muller A, Dubourg O, Seilhan D, Hauw JJ, Loeffler JP, et al.: Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neural 2005, 57:533-536.

91. Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, Dupuis L, Jokic N, Salachas F, Le Forestier N, Echaniz-Laguna A, Dubourg O, Hauw JJ, et al.: Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neural 2007, 62:15-20.

92. Wojcik S, Engel WK, Askanas V: Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease. Acta Myol 2006, 25:116-118.

93. Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, Schwab ME, Dupuis L, Loeffler JP: The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006, 7:1162-1167.

94. Magnusson C, Libelius R, Tagerud S: Nogo (Reticulon 4) expression in innervated and denervated mouse skeletal muscle. Mol Cell Neurosci 2003, 22:298-307.

95. Reindl M, Khantane S, Ehling R, Schanda K, Lutterotti A, Brinkhoff C, Oertle T, Schwab ME, Deisenhammer F, Berger T, et al.: Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuromunual 2003, 145:139-147.

96. Karnezis T, Mandemakers W, McQuilter JL, Zheng B, Ho PP, Jordan KA, Murray BM, Barres B, Tessier-Lavigne M, Bernard CC: The neurite outgrowth inhibitor Nogo-A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004, 7:736-744.

97. Mannan AU, Krawen P, Sauter SM, Boehm J, Chronowska A, Paulus W, Neesen J, Engel W: ZFYVE27 (SPG33), a novel spastin-binding protein, is mutated in hereditary spastic paraplegia. Am J Hum Genet 2006, 79:351-357.

98. Mannan AU, Boehm J, Sauter SM, Rauber A, Byrne PC, Neesen J, Engel W: Spastin, the most commonly mutated protein in hereditary spastic paraplegia interacts with Reticulon 1 an endoplasmic reticulum protein. Neurogenetics 2006, 7:93-103.

99. ClustalW2 [http://www.ebi.ac.uk/Tools/clustalw2]

100. Phylo_win [http://pbil.univ-lyon1.fr/software/phylowin.html]